Xu J, Song S, Tang Z
Beijing North Taiping Road Hospital Cancer Center.
Zhonghua Zhong Liu Za Zhi. 1997 Mar;19(2):153-6.
The predictive value of in vitro MTT assay for chemotherapy to breast cancer patients was studied.
Of the 156 advanced breast cancer patients, 83 had had MTT assay before chemotherapy. According to the result of the MTT assay, 73 patients in MTT sensitive group received chemotherapy. The other 10 patients in MTT resistant group and 73 patients in the control group were given chemotherapy according to clinician' experience.
The response rate in MTT sensitive group was 76.7% (56/73). There was statistically significant difference as compared with 0(0/10) in the resistant group and 43.8% (32/73) in the control group. Between MTT sensitive group and control group, similar results were obtained at different therapeutic phases, in the subgroups of most lesions and chemotherapeutic schemes. Both the relapse rate and mortality rate were reduced remarkably in the MTT sensitive group. But there was no difference in the median remission and survival of relapsed patients in the two groups. Between in vitro and in vivo, the overall coincident rate was 79.5% [(56 + 10)/83].
The in vitro MTT assay can predict chemotherapy for breast cancer giving satisfactory results.
研究体外MTT法对乳腺癌患者化疗的预测价值。
156例晚期乳腺癌患者中,83例在化疗前进行了MTT检测。根据MTT检测结果,MTT敏感组73例患者接受化疗。MTT耐药组的另外10例患者和对照组的73例患者根据临床医生的经验进行化疗。
MTT敏感组的有效率为76.7%(56/73)。与耐药组的0(0/10)和对照组的43.8%(32/73)相比,差异有统计学意义。在MTT敏感组和对照组之间,在不同治疗阶段、大多数病变亚组和化疗方案中均得到了相似的结果。MTT敏感组的复发率和死亡率均显著降低。但两组复发患者的中位缓解期和生存期无差异。体外和体内的总体符合率为79.5%[(56 + 10)/83]。
体外MTT法可对乳腺癌化疗进行预测,结果满意。